SCHEMBL20908673

SCHEMBL20908673

Cc1cnc(Nc2cc(CN3CCOCC3)cc(-c3cccc(NC(=O)OC(C)(C)C)c3)n2)s1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.41
HDAC3 O15379 4/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC2 Q92769 3/20 0.40
HDAC10 Q969S8 3/20 0.40
HDAC8 Q9BY41 2/20 0.40
BRAF P15056 2/20 0.40
CNR2 P34972 1/20 0.40
KDR P35968 3/20 0.39
CHEK1 O14757 1/20 0.39
ALK Q9UM73 1/20 0.39
LCK P06239 2/20 0.38
CD274 Q9NZQ7 1/20 0.38
EGFR P00533 1/20 0.38
FLT3 P36888 3/20 0.38
KIT P10721 2/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22206182 0.90 JAK3 (0.45) JAK3BRAFCNR2KDRCHEK1
SCHEMBL20908740 0.87 EGFR (0.52) JAK3EGFRAURKA
SCHEMBL20908661 0.85 KDR (0.38) JAK3CNR2KDRCHEK1ALK
SCHEMBL22215290 0.85 KDR (0.44) JAK3KDRCHEK1CD274FLT3
SCHEMBL24383588 0.83 CNR2 (0.39) JAK3HDAC3HDAC1HDAC2HDAC10
SCHEMBL28893696 0.82 CHEK1 (0.42) JAK3CNR2KDRCHEK1ALK
SCHEMBL20908967 0.82 SMN1; SMN2 (0.46) JAK3HDAC3HDAC1HDAC2HDAC10
SCHEMBL29743061 0.80 CHEK1 (0.46) JAK3KDRCHEK1ALKLCK
SCHEMBL23921963 0.80 CHEK1 (0.46) JAK3KDRCHEK1ALKLCK
SCHEMBL29838449 0.80 KDR (0.44) JAK3CNR2KDRCHEK1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3696176-B1 NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DAE WOONG PHARMA (KR) 2022-05-04 EP disclosed
US-11149019-B2 Phenylpyridine derivative and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-10-19 US disclosed
EP-3696176-A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2020-08-19 EP disclosed
US-20200223821-A1 Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-16 US disclosed
WO-2019074275-A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 주식회사 대웅제약 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223821-A1 Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same PDCD1, PDCD5, PDCD11 JAK3 811/4885HDAC3 1607/4885HDAC1 295/4885
US-11149019-B2 Phenylpyridine derivative and pharmaceutical composition comprising the same DPYD, PDCD5, PDCD1 JAK3 869/4885HDAC3 1719/4885HDAC1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.